Phase III clinical trial is evaluating RenovoGem™ for the treatment of Locally Advanced Pancreatic Cancer
UNMC opened enrollment of TIGeR-PaC in June 2024 and joins esteemed clinical sites throughout United States participating in the study
Read more at globenewswire.comRENOVORX INC
NASDAQ:RNXT (2/7/2025, 8:00:01 PM)
After market: 1.16 0 (0%)1.16
-0.3 (-20.55%)
16 hours ago - ChartmillWhat's going on in today's pre-market sessionDiscover the top movers in Friday's pre-market session and stay informed about market dynamics.
a day ago - ChartmillThese stocks are moving in today's after hours sessionLet's have a look at what is happening on the US markets after the closing bell on Thursday. Below you can find the top gainers and losers in today's after hours session.
